Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.
Publication
, Conference
Desjardins, A; Sampson, J; Peters, K; Vlahoci, G; Randazzo, D; Threatt, S; Herndon, J; Boulton, S; Lally-Goss, D; McSherry, F; Friedman, A ...
2068
Duke Scholars
Volume
33
Issue
15s, Part I of II
Start / End Page
112s / 112s
Location
McCormick Place, Chicago, IL
Conference Name
2015 American Society of Clinical Oncology Annual Meeting
Citation
APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Sampson, J., Peters, K., Vlahoci, G., Randazzo, D., Threatt, S., … Gromeier, M. (n.d.). Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination. (Vol. 33, pp. 112s-112s). Presented at the 2015 American Society of Clinical Oncology Annual Meeting, McCormick Place, Chicago, IL.
Desjardins, Annick, John Sampson, Katherine Peters, Gordana Vlahoci, Dina Randazzo, Stevie Threatt, James Herndon, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.,” 33:112s-112s, n.d.
Desjardins A, Sampson J, Peters K, Vlahoci G, Randazzo D, Threatt S, et al. Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination. In p. 112s-112s.
Desjardins, Annick, et al. Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination. Vol. 33, no. 15s, Part I of II, pp. 112s-112s.
Desjardins A, Sampson J, Peters K, Vlahoci G, Randazzo D, Threatt S, Herndon J, Boulton S, Lally-Goss D, McSherry F, Friedman A, Friedman H, Bigner D, Gromeier M. Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination. p. 112s-112s.
Volume
33
Issue
15s, Part I of II
Start / End Page
112s / 112s
Location
McCormick Place, Chicago, IL
Conference Name
2015 American Society of Clinical Oncology Annual Meeting